Drug Trial Radar · NCT06467201
SAD Study to Evaluate Safety, Tolerability, and Pharmacokinetic Profile of AMN1126 in Healthy Post-Menopausal Females
Last checked: Nov 20, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Jun 3, 2024
Primary completion
Dec 8, 2024
Study completion Mar 12, 2025
Sponsor
- Lead sponsor
- Amneal Pharmaceuticals, LLCIndustry
- Sponsor type
- Industry
- First posted
- Jun 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 45 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an Open-label, Sequential dosing, Single Ascending Dose (SAD) Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of KSHN001126 in Healthy Human Post-Menopausal Female Volunteers. The primary objective of the study is to evaluate the safety and tolerability of increasing single doses of KSHN001126 while the secondary objective is to evaluate the plasma PK profile of KSHN001126 and its metabolites (KSHN001167, KSHN001168 and Fulvestrant) following ascending single oral doses of KSHN001126.
Conditions
- Healthy Postmenopausal Women
Interventions
KSHN001126 150mgDrug
6 subjects will receive single oral dose of 150mg
KSHN001126 300mgDrug
6 subjects will receive single oral dose of 300mg
KSHN001126 600mgDrug
6 subjects will receive single oral dose of 600mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Type, incidence, severity, seriousness, and relatedness of Adverse Events (AEs)Time frame: Upto Day 15 after dosing
- Number of participants with abnormal laboratory tests resultsTime frame: Upto Day 15 after dosing
- Number of participants with abnormal vital signsTime frame: Upto Day 15 after dosing
- Number of participants with abnormal Electrocardiogram readingsTime frame: Upto Day 15 after dosing
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Advanced Pharma CR
Miami, Florida
Health1 Superspeciality Hospital
Ahmedabad, Gujarat, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.